Epilepsy, Seizures
Conditions
Brief summary
The purpose of this study is to evaluate the safety and tolerability of Epidiolex at various doses between 5 mg/kg/day and 50 mg/kg/day as an additional (add-on) drug for treating debilitating, drug-resistant epilepsy.
Detailed description
The specific goals of this phase I dose finding study, conducted in consecutively enrolled patients 1-19 years of age, are to prospectively and longitudinally assess the safety and tolerability, including cognitive effects, of Cannabidiol (CBD) at various doses between 5 mg/kg/day and 25 mg/kg/day, with additional titration in some cases up to 50 mg/kg/day. In order to participate in the study, participants will need to fulfill the inclusion and exclusion criteria. The goal of the study is to fulfill the mandate of Carly's Law and to provide patients with debilitating epileptic conditions with access to CBD as an add-on treatment. Other care including routine neurological care unrelated to participation in the CBD study will need to be provided by patients' primary/current treating neurologist.
Interventions
DRUGEpidiolex
Epidiolex oral solution (100 mg/mL CBD concentration) with inactive ingredients including anhydrous ethanol, sesame seed oil, strawberry flavor, and sucralose).
Sponsors
University of Alabama at Birmingham
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to 19 Years
Healthy volunteers
No
Inclusion criteria
* Patients between 1 years (12 months)-18 years with drug resistant epilepsy confirmed by video EEG recording report, and * Patient should have history of a trial of at least four anti-epileptic drugs (AEDs), including one trial of a combination of two concomitant drugs without successful seizure control. Vagal nerve stimulation (VNS), Responsive Neurostimulation (RNS) deep brain stimulation, or the ketogenic diet can be considered equivalent to a drug trial. Patient suffering from an epileptic syndrome that is known to be refractory to treatment, such as Dravet or Lennox-Gastaut Syndrome, may be included after a trial of only two drugs, and * Between 1-4 baseline anti-epileptic drugs at stable doses for a minimum of 4 weeks prior to submitting records for review by the CBD Treatment Approval Committee. * VNS or RNS must be on stable settings for a minimum of 3 months. * If on ketogenic diet, must be on stable ration for a minimum of 3 months. * Review of the following patient medical information: * Most recent Brain MRI report, * Most recent ECG report, * Video/EEG monitoring report confirming the diagnosis of epilepsy, * Evidence that the patient has failed 4 AEDs as indicated above, * Patient must have at least 4 clinically countable seizures per month, * Seizure history to include a documented history of generalized (drop, atonic, tonic clonic, and/or myoclonic) seizures, focal seizures without loss of consciousness with a motor component, focal seizures with loss of consciousness, or focal seizures with secondary generalization, complex partial seizures with a motor or tonic component, and I or altered awareness seizures, * Results of routine testing including blood work (Complete Blood Count (CBC), Comprehensive Metabolic Panel (CMP), Liver Function Tests (LFTs), renal panel, Urinary Analysis (UA), and levels of all AEDs) and digital copy of a routine EEG along with the formal written report performed within 3 months prior to submitting records for CBD Treatment Approval review. If applicable, results of any metabolic or genetic testing performed should be included in submitted records for review. If any AED dose was adjusted in the preceding 3 months, level on the new dose will need to be provided. * If applicable, documentation (including date of surgery) of prior VNS, RNS, Corpus Callosotomy, or other epilepsy surgery the patient has received. * Acceptable method of contraception (or abstinence) for women of childbearing potential and for male patients with partners of childbearing potential, and female patients must have a negative urine pregnancy test on the day of initiating CBD. * For patients who agree to participate in the optional neuroimaging sub-study, an MRI screen will be obtained to show that the patient does not have contraindication to receiving MRI/functional MRI (fMRI) at 3 Tesla (e.g., metallic artifact). * Patients are able to supply investigator with seizure calendars for the past 3 months prior to submitting records for CBD Treatment Approval Committee review. The patient will need to provide an updated calendar at the time of enrollment. * Approval for inclusion by the CBD Treatment Approval Committee. * Current State of Alabama Resident * Acceptable documentation of Alabama residency includes the following: * a state issued identification (ID), such as a driver's license, from patient or patient's parent/ legally authorized representative (LAR). * documents showing the patient or patient's parent/LAR rents/owns property in the state, * state voter registration from patient or patient's parent/LAR, or * a recent state tax return from patient or patient's parent/LAR.
Exclusion criteria
* Active Psychogenic non-epileptic seizures (PNES); Patients with more than 1 year freedom from PNES will not be excluded, * Patients who are pregnant, breastfeeding, or not using acceptable methods of contraception during the course of the study and for three months thereafter, * Male patient's partner is of child bearing potential; unless willing to ensure that they (male patients) or their partner(s) are using acceptable methods of contraception during the course of the study and for three months thereafter * History of substance abuse/addiction, * Use of medical marijuana or CBD based product in the past 30 days, * Initiation of felbamate within last 12 months, * Allergy to CBD or any marijuana-type products, * Alanine Aminotransferase (ALT) \>5 x Upper Limit of Normal (ULN) or Aspartate Aminotransferase (AST) \>5 x ULN, as seen in participant's laboratory results submitted to the CBD Treatment Approval Committee for review. * Hemoglobin \<10 or Hematocrit \<30 or White Blood Cell (WBC) \< 2000, as seen in participant's laboratory results submitted to the CBD Treatment Approval Committee for review. * In Investigator's judgement, active medical condition/treatment that impacts study activities. * Unable to provide consent (and no LAR), * Unable/Failure to comply with study visits/requirements and/or instructions. * Confirmed diagnosis for Dravet Syndrome or Lennox-Gastaut Syndrome that qualifies the patient for a Greenwich (GW) Dravet Syndrome or Lennox-Gastaut Syndrome randomized controlled clinical trial for which the patient is eligible pursuant to the GW clinical trial enrollment criteria unless * (a) there is no study that is either actively open for enrollment of patients at The University of Alabama at Birmingham (UAB) or that is expected to actively begin enrolling patients at UAB within two (2) months of the date on which the patient is screened for the UAB Pediatric CBD Program or UAB Adult CBD Program. Primary residence in a State different than Alabama. * Subjects with contraindications to MRI/fMRI at 3 Tesla (e.g., metallic artifact) will not be offered participation in the optional sub-study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Severe Adverse Events (Increase in Seizure Frequency by More Than 100% Leading to Emergency Room Visit or Hospitalization). | For 1 Year following Enrollment | Severe adverse events (SAEs) were defined as increase in seizure frequency by more than 100% leading to emergency room visit or hospitalization. During study clinic and phone visits, adverse and severe adverse event monitoring and reporting were assessed among all participants. Data was recorded and stored in the UAB RedCap System. |
| Number of Participants With Change in Resting Blood Pressure or Heart Rate by 25% if Considered Significant by Managing Neurologist. | For 1 Year following Enrollment | During study clinic visits, participant vital signs, including blood pressure and heart rate, were collected. Data was recorded and stored in the UAB RedCap System. Clinically significant was determined by using the Common Toxicity Criteria for Adverse Events (CTCAE) Version 4.03. Adverse events categorized as a grade 3 or above were considered clinically significant. Adverse events grade 4 or above were considered severe adverse events. |
| Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | For 1 Year following Enrollment | During study clinic visits, participants received laboratory testing to assess for side effects and toxicity. Data was recorded and stored in the UAB RedCap System. Laboratory testing included Complete Blood Count (CBC), Comprehensive Metabolic Panel (CMP; included Liver Function Tests (LFTs) mainly looking at alanine aminotransferase (ALT) and aspartate aminotransferase (AST)), Urine Analysis (UA), and Antiepileptic Drug (AED) levels. Clinically significant was determined by using the Common Toxicity Criteria for Adverse Events (CTCAE) Version 4.03. Adverse events categorized as a grade 3 or above were considered clinically significant. Adverse events grade 4 or above were considered severe adverse events. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Seizure Frequency as Measured in Total Number of Seizures Per Month. | For 1 Year following Enrollment | Participants were given seizure diary logs and dairy data collection was done at study clinic visits. Data was recorded and stored in the UAB RedCap System. The analysis plan was to assess the pattern of change in seizure frequency over time, relative to baseline, following CBD exposure. Since the baseline measure was reported at the time of screening, there was some tendency to overestimate the frequency of seizures in the historically reported interval. This was examined by comparing the initial study visits improvement versus the pattern of control over time, and was assessed using graphic techniques and summary statistics. |
| Change in Seizure Severity Measured by the Chalfont Seizure Severity Scale (Duncan & Sander, 1991, JNNP). | For 1 Year following Enrollment | Seizure severity was collected during study clinic and phone visits using the Chalfont Seizure Severity Scale (CSSS) (Duncan & Sander, 1991, JNNP) through verbal reporting. The CSSS measured components of seizures most disturbing or disruptive to the participants. The total scores for a given seizure type was its severity score. High scores indicated high severity of the seizures (no fixed maximum value), while a score of zero indicated low severity. Scores were recorded and stored in the UAB RedCap System. The analysis plan was to assess the pattern of change in seizure severity scores over time, relative to baseline, following CBD exposure. Since the baseline measure was reported at the time of screening, there was some tendency to overestimate the severity of seizures in the historically reported interval. This was examined by comparing the initial study visits improvement versus the pattern of control over time, and was assessed using graphic techniques and summary statistics. |
Countries
United States
Participant flow
Recruitment details
Participants with treatment-resistant epilepsy in the state of Alabama were enrolled. Their primary treating neurologist provided the UAB CBD Treatment Approval Committee with the required information (found on www.uab.edu/cbd) to review. The committee either approved/recommended or disapproved/not recommended them for treatment in the study.
Pre-assignment details
Of the total 141 participants with epilepsy ages 1-19 screened, 89 were enrolled in this single-center, open-label study. This study was not randomized.
Participants by arm
| Arm | Count |
|---|---|
| Epidiolex The participants (or their caregivers) self-administered CBD 100mg/mL oral solution at a starting dose of 5 mg/kg/day in twice daily dosing and titrated by 5 mg/kg/2 weeks up to 25 mg/kg/day. Additional increases in dosing, by 5 mg/kg/day up to a maximum of 50 mg/kg/day, was instituted at the discretion of the treating PI. | 89 |
| Total | 89 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 3 |
| Overall Study | Lack of Efficacy | 28 |
| Overall Study | Protocol Violation | 3 |
| Overall Study | Withdrawal by Subject | 4 |
Baseline characteristics
| Characteristic | Epidiolex |
|---|---|
| Age, Continuous | 9.7978 years STANDARD_DEVIATION 4.9087 |
| Race/Ethnicity, Customized Asian | 3 Participants |
| Race/Ethnicity, Customized Black or African American | 14 Participants |
| Race/Ethnicity, Customized White | 72 Participants |
| Sex: Female, Male Female | 48 Participants |
| Sex: Female, Male Male | 41 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 89 |
| other Total, other adverse events | 82 / 89 |
| serious Total, serious adverse events | 15 / 89 |
Outcome results
Primary
Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant.
During study clinic visits, participants received laboratory testing to assess for side effects and toxicity. Data was recorded and stored in the UAB RedCap System. Laboratory testing included Complete Blood Count (CBC), Comprehensive Metabolic Panel (CMP; included Liver Function Tests (LFTs) mainly looking at alanine aminotransferase (ALT) and aspartate aminotransferase (AST)), Urine Analysis (UA), and Antiepileptic Drug (AED) levels. Clinically significant was determined by using the Common Toxicity Criteria for Adverse Events (CTCAE) Version 4.03. Adverse events categorized as a grade 3 or above were considered clinically significant. Adverse events grade 4 or above were considered severe adverse events.
Time frame: For 1 Year following Enrollment
Population: Per protocol, after all participants have been enrolled and followed for 1 year.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CBC: ABS Monocytes | 1 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Clorazepate Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Lamotrigine Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CBC: White Blood Cell (WBC) Count | 4 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CBC: Red Blood Cell (RBC) Count | 1 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CBC: Hemoglobin | 2 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CBC: Hematocrit | 2 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CBC: Platelet | 3 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CBC: Absolute (ABS) Neutrophils | 2 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CBC: ABS Lymphocytes | 1 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CBC: Neutrophils | 1 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CBC: Lymphocytes | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CMP: Serum Creatinine | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CMP: Creatinine Clearance | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CMP: ALT (SGPT) | 11 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CMP: AST (SGOT) | 8 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CMP: Total Bilirubin | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CMP: Direct Bilirubin | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CMP: Blood Urea Nitrogen (BUN) | 1 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CMP: Albumin | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CMP: Alkaline Phosphate | 1 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CMP: Sodium | 2 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CMP: Glucose | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CMP: Calcium | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CMP: Carbon Dioxide | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CMP: Chloride | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | CMP: Potassium | 1 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | UA: Specific Gravity | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | UA: PH | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | UA: Leukocyte Esterase | 27 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | UA: Nitrite | 3 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | UA: Protein | 21 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | UA: Glucose | 5 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | UA: Ketones | 27 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | UA: Urubilinogen | 21 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | UA: Bilirubin | 4 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | UA: Blood | 18 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Phenobarbital Level | 1 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Primidone Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Klonopin Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Clobazam Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Desmethylclobazam Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Lorazepam Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Phenytoin Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Carbamazepine Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Valproate Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Felbamate Level | 1 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Gabapentin Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Levetiracetam Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Oxcarbazepine Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Ethosuximide Level | 1 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Tiagabine Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Topiramate Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Vigabatrin Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Zonisamide Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Eslicarbazepine Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Ezogabine Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Pregabalin Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Perampanel Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Rufinamide Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Brivaracetam Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Lacosamide Level | 0 Participants |
| Epidiolex | Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant. | AED: Diazepam Level | 0 Participants |
Primary
Number of Participants With Change in Resting Blood Pressure or Heart Rate by 25% if Considered Significant by Managing Neurologist.
During study clinic visits, participant vital signs, including blood pressure and heart rate, were collected. Data was recorded and stored in the UAB RedCap System. Clinically significant was determined by using the Common Toxicity Criteria for Adverse Events (CTCAE) Version 4.03. Adverse events categorized as a grade 3 or above were considered clinically significant. Adverse events grade 4 or above were considered severe adverse events.
Time frame: For 1 Year following Enrollment
Population: Per protocol, after all participants have been enrolled and followed for 1 year.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Epidiolex | Number of Participants With Change in Resting Blood Pressure or Heart Rate by 25% if Considered Significant by Managing Neurologist. | Blood Pressure | 0 Participants |
| Epidiolex | Number of Participants With Change in Resting Blood Pressure or Heart Rate by 25% if Considered Significant by Managing Neurologist. | Heart Rate | 0 Participants |
Primary
Number of Participants With Severe Adverse Events (Increase in Seizure Frequency by More Than 100% Leading to Emergency Room Visit or Hospitalization).
Severe adverse events (SAEs) were defined as increase in seizure frequency by more than 100% leading to emergency room visit or hospitalization. During study clinic and phone visits, adverse and severe adverse event monitoring and reporting were assessed among all participants. Data was recorded and stored in the UAB RedCap System.
Time frame: For 1 Year following Enrollment
Population: Per protocol, after all participants have been enrolled and followed for 1 year.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Epidiolex | Number of Participants With Severe Adverse Events (Increase in Seizure Frequency by More Than 100% Leading to Emergency Room Visit or Hospitalization). | 0 Participants |
Secondary
Change in Seizure Frequency as Measured in Total Number of Seizures Per Month.
Participants were given seizure diary logs and dairy data collection was done at study clinic visits. Data was recorded and stored in the UAB RedCap System. The analysis plan was to assess the pattern of change in seizure frequency over time, relative to baseline, following CBD exposure. Since the baseline measure was reported at the time of screening, there was some tendency to overestimate the frequency of seizures in the historically reported interval. This was examined by comparing the initial study visits improvement versus the pattern of control over time, and was assessed using graphic techniques and summary statistics.
Time frame: For 1 Year following Enrollment
Population: Per protocol, after all participants have been enrolled and followed for 1 year. Number of participants analyzed differed because: 1) Those who responded to a certain CBD dose had fewer monthly visits; 2) Those who decided to continue on the same CBD dose had fewer monthly visits; or 3) Withdrawal prior to 1 year following enrollment.
| Arm | Measure | Group | Value (GEOMETRIC_LEAST_SQUARES_MEAN) |
|---|---|---|---|
| Epidiolex | Change in Seizure Frequency as Measured in Total Number of Seizures Per Month. | Month 11 vs Baseline | 0.38 number of seizures/month |
| Epidiolex | Change in Seizure Frequency as Measured in Total Number of Seizures Per Month. | Month 1 vs Baseline | 0.63 number of seizures/month |
| Epidiolex | Change in Seizure Frequency as Measured in Total Number of Seizures Per Month. | Month 2 vs Baseline | 0.44 number of seizures/month |
| Epidiolex | Change in Seizure Frequency as Measured in Total Number of Seizures Per Month. | Month 3 vs Baseline | 0.38 number of seizures/month |
| Epidiolex | Change in Seizure Frequency as Measured in Total Number of Seizures Per Month. | Month 4 vs Baseline | 0.38 number of seizures/month |
| Epidiolex | Change in Seizure Frequency as Measured in Total Number of Seizures Per Month. | Month 5 vs Baseline | 0.4 number of seizures/month |
| Epidiolex | Change in Seizure Frequency as Measured in Total Number of Seizures Per Month. | Month 6 vs Baseline | 0.41 number of seizures/month |
| Epidiolex | Change in Seizure Frequency as Measured in Total Number of Seizures Per Month. | Month 7 vs Baseline | 0.42 number of seizures/month |
| Epidiolex | Change in Seizure Frequency as Measured in Total Number of Seizures Per Month. | Month 8 vs Baseline | 0.41 number of seizures/month |
| Epidiolex | Change in Seizure Frequency as Measured in Total Number of Seizures Per Month. | Month 9 vs Baseline | 0.41 number of seizures/month |
| Epidiolex | Change in Seizure Frequency as Measured in Total Number of Seizures Per Month. | Month 10 vs Baseline | 0.39 number of seizures/month |
| Epidiolex | Change in Seizure Frequency as Measured in Total Number of Seizures Per Month. | Month 12 vs Baseline | 0.36 number of seizures/month |
Comparison: Null hypothesis is that there was no change in seizure frequency between any two assessment time points during this period of analysis. Alternative hypothesis is that there were two or more assessment time points for which change in seizure frequency was different from zero.p-value: <0.0001Wilcoxon (Mann-Whitney)
Secondary
Change in Seizure Severity Measured by the Chalfont Seizure Severity Scale (Duncan & Sander, 1991, JNNP).
Seizure severity was collected during study clinic and phone visits using the Chalfont Seizure Severity Scale (CSSS) (Duncan & Sander, 1991, JNNP) through verbal reporting. The CSSS measured components of seizures most disturbing or disruptive to the participants. The total scores for a given seizure type was its severity score. High scores indicated high severity of the seizures (no fixed maximum value), while a score of zero indicated low severity. Scores were recorded and stored in the UAB RedCap System. The analysis plan was to assess the pattern of change in seizure severity scores over time, relative to baseline, following CBD exposure. Since the baseline measure was reported at the time of screening, there was some tendency to overestimate the severity of seizures in the historically reported interval. This was examined by comparing the initial study visits improvement versus the pattern of control over time, and was assessed using graphic techniques and summary statistics.
Time frame: For 1 Year following Enrollment
Population: Per protocol, after all participants have been enrolled and followed for 1 year. Number of participants analyzed differed because: 1) Those who responded to a certain CBD dose had fewer monthly visits; 2) Those who decided to continue on the same CBD dose had fewer monthly visits; or 3) Withdrawal prior to 1 year following enrollment.
| Arm | Measure | Group | Value (GEOMETRIC_LEAST_SQUARES_MEAN) |
|---|---|---|---|
| Epidiolex | Change in Seizure Severity Measured by the Chalfont Seizure Severity Scale (Duncan & Sander, 1991, JNNP). | Month 2 vs Baseline | 0.47 scores on a scale |
| Epidiolex | Change in Seizure Severity Measured by the Chalfont Seizure Severity Scale (Duncan & Sander, 1991, JNNP). | Month 1 vs Baseline | 0.66 scores on a scale |
| Epidiolex | Change in Seizure Severity Measured by the Chalfont Seizure Severity Scale (Duncan & Sander, 1991, JNNP). | Month 3 vs Baseline | 0.37 scores on a scale |
| Epidiolex | Change in Seizure Severity Measured by the Chalfont Seizure Severity Scale (Duncan & Sander, 1991, JNNP). | Month 4 vs Baseline | 0.35 scores on a scale |
| Epidiolex | Change in Seizure Severity Measured by the Chalfont Seizure Severity Scale (Duncan & Sander, 1991, JNNP). | Month 5 vs Baseline | 0.36 scores on a scale |
| Epidiolex | Change in Seizure Severity Measured by the Chalfont Seizure Severity Scale (Duncan & Sander, 1991, JNNP). | Month 6 vs Baseline | 0.4 scores on a scale |
| Epidiolex | Change in Seizure Severity Measured by the Chalfont Seizure Severity Scale (Duncan & Sander, 1991, JNNP). | Month 7 vs Baseline | 0.43 scores on a scale |
| Epidiolex | Change in Seizure Severity Measured by the Chalfont Seizure Severity Scale (Duncan & Sander, 1991, JNNP). | Month 8 vs Baseline | 0.44 scores on a scale |
| Epidiolex | Change in Seizure Severity Measured by the Chalfont Seizure Severity Scale (Duncan & Sander, 1991, JNNP). | Month 9 vs Baseline | 0.45 scores on a scale |
| Epidiolex | Change in Seizure Severity Measured by the Chalfont Seizure Severity Scale (Duncan & Sander, 1991, JNNP). | Month 10 vs Baseline | 0.46 scores on a scale |
| Epidiolex | Change in Seizure Severity Measured by the Chalfont Seizure Severity Scale (Duncan & Sander, 1991, JNNP). | Month 11 vs Baseline | 0.46 scores on a scale |
| Epidiolex | Change in Seizure Severity Measured by the Chalfont Seizure Severity Scale (Duncan & Sander, 1991, JNNP). | Month 12 vs Baseline | 0.46 scores on a scale |
Comparison: Null hypothesis is that there was no change in seizure severity scores between any two assessment time points during this period of analysis. Alternative hypothesis is that there were two or more assessment time points for which change in seizure severity scores was different from zero.p-value: <0.0001Wilcoxon (Mann-Whitney)